May 20th, 2019
Abiomed, the maker of popular left ventricular assist devices, is releasing its newly FDA approved Impella CP with SmartAssist device. The pump features an optical sensor that physicians can use to position and reposition the device without relying on a cath lab, X-ray, or ultrasound imaging. The sensor can be used either during...
September 25th, 2017Abiomed won FDA approval for its Impella RP heart pump, the first percutaneous temporary ventricular support device indicated for right heart failure. The device moves blood from the inferior vena cava into the pulmonary artery, doing the work of the right ventricle. It's inserted via the femoral vein and pushed up and through the...
May 10th, 2017
Abiomed, the maker of implantable cardiac assistive devices, has just announced its new 3rd generation Impella CP heart pump. The device is designed to assist the native heart during percutaneous coronary interventional (PCI) procedures that can be difficult to tolerate for fragile patients, as well as to stabilize those post...
March 24th, 2015Abiomed received FDA approval for its Impella 2.5 heart pump to be used during elective and urgent high risk percutaneous coronary interventions. The device moves 2.5 liters of blood per minute, assisting the left ventricle during procedures involving temporary coronary occlusions that would otherwise be too taxing on the already weak...
January 28th, 2015
The FDA granted Abiomed a Humanitarian Device Exemption approval for the company's Impella RP (Right Percutaneous) System. This is the first FDA approved percutaneous single access heart pump that's intended for supporting the right side of the heart. It is capable of augmenting by up to four liters of blood per minute and is indicated...
April 9th, 2014
ABIOMED, a big name in heart-assist pump technology, just received European approval of its Impella RP pump that, unlike most other similar devices, is designed to specifically support the right ventricle. It's marked for use for up to 14 days to compensate for reduced right ventricular function, after heart attacks, during beating...
September 10th, 2012Abiomed has announced that it's now offering its more powerful Impella heart pump in the U.S., the 4L/min Impella CP (Cardiac Power). In Europe the device is known as Impella cVAD and it's been cleared with a CE Mark in April of this year.
The Impella CP is built on the same foundation as the Impella 2.5, but provides more than a 50%...
April 18th, 2012Abiomed received the European CE Mark to make available its Impella cVAD heart pump on the continent.
The device looks and behaves just like the popular Impella 2.5 pump, but is more powerful with a maximum blood flow of 4 liters per minute versus 2.5 for its sibling. And just like the Impella 2.5, the Impella cVAD is percutaneously...
December 21st, 2011Abiomed's Impella left ventricular assist device, an endovascular percutaneously-delivered LVAD, will soon be getting a more powerful sister model. The current model is capable of delivering an augmentation of cardiac output by up to 2.5 liters a minute, but the new Impella cVAD should do around 3.5 L/m, and possibly up to 4 L/m in the...
November 11th, 2011Cost scrutiny and comparative effectiveness research are playing a growing role in shaping healthcare delivery. In light of that, Abiomed Inc. (Danvers, MA) has recently announced the results of a study that showed the company's Impella heart pump significantly reduced major adverse events at an incremental cost per quality-adjusted...
December 7th, 2010
Abiomed's Impella 2.5 Percutaneous Circulatory Support System, the world's smallest left ventricle heart pump, has received conditional approval from the FDA to begin MINI-AMI, "a prospective, randomized, controlled multi-site trial to assess the potential role of the Impella® 2.5 in reducing infarct size in patients with...
